stockrow
Friday 6 November 2026
Export NORD’s income statement to Excel — free account
Nordicus Partners Corporation
NORD Healthcare Biotechnology
Nordicus Partners Corporation’s revenue for fiscal 2025 (year ended March 2025) was $5,000.00, up 100.0% from fiscal 2024.
- Revenue
- −99.6%
- EPS
- −85.7%
- Free cash flow
- +62.2%
Quarter to June 2026, against a year earlier
3.40
0.33
−8.85%
Follow NORD
Alert me
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
— | — | — | — |
EV/Sales |
— | — | — | — | |
EV/FCF |
— | — | — | — | |
Quick Ratio |
0.24 | 0.21 | 0.02 | 0.00 | |
Current Ratio |
0.48 | 0.71 | 0.46 | 0.18 | |
Net Debt/EBITDA |
0.20 | 0.17 | 0.02 | 0.01 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
1.17 | 1.19 | 12.03 | 0.07 | |
Capex/Depreciation |
(54.00) | (0.35) | 1.13 | (0.92) | |
Interest Coverage |
— | (5,611.00) | (3,013.75) | (431.37) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.37 | 0.36 | 0.36 | 0.37 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | — | |
Free Cash Flow Yield |
— | — | — | — | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.10) | (0.08) | (0.04) | (0.01) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.10) | (0.08) | (0.04) | (0.01) | |
Cash per Share |
0.01 | 0.01 | 0.00 | 0.00 | |
Shareholders Equity per Share |
3.62 | 3.48 | 3.54 | 3.21 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
3.62 | 3.48 | 3.54 | 3.21 | |
Free Cash Flow |
(1.77) | (1.46) | (0.67) | (0.16) | |
Working Capital |
(0.52) | (0.26) | (0.64) | (1.37) | |
Capital Expenditures |
(0.01) | 0.00 | 0.00 | 0.00 | |
Net Current Asset Value |
(10.73) | (10.46) | (10.69) | (11.29) | |
EV/EBIT |
— | — | — | — | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Payables |
0.58 | 0.76 | 1.09 | 1.60 | |
Average Assets |
48.33 | 67.79 | 72.85 | 74.61 | |
Average Common Equity |
42.65 | 61.79 | 62.05 | 62.89 |
Columns are period end dates · fundamentals updated 2 Nov 2026